Siemens Healthcare Diagnostics Products Gmbh

Siemens Healthcare Diagnostics Gmbh

Frank Vitzthum

Herbert Schwarz

Harald Althaus

Stefan Teigelkamp

Andreas Kappel

Gerlinde Christ

Anja Haude-Barten

Katharina Dekevic

Lena Pechmann

Michelle Son

Huey Lee

Disclosed herein are compositions and methods for removing interfering substances from biological samples, biochemical assays, or reagents used in biological samples using porous liposomes that capture and in some instances enrich said interfering substances within the liposomes.

Compositions and methods for removing interfering substances

A method and kit are provided herein for determining the ADAMTS-13 activity in a sample. The method comprises contacting the sample with a von Willebrand factor (VWF) polypeptide which has been coupled to a reporter enzyme, such as glucose-6-phosphate dehydrogenase (G6PDH).

Enzyme-enhanced ADAMTS-13 activity assay

Methods for detection and quantitative measurement of proteins with a Coomassie Brilliant Blue Assay with improved sensitivity and maintaining high linearity over a broad measuring range are provided herein. In particular, a method of detecting a protein in a protein-containing sample is provided. The method includes providing a sample including a protein, a reagent including Coomassie Brilliant Blue and having a pH between 0.85 and 1.1, combining the sample and the reagent, and determining absorption at first and second wavelength to determine the amount of protein in the sample. The ratio of the absorption value at the first wavelength between about 580 to 620 nm to the absorption value at the second wavelength between about 520 to 370 nm is used in the spectral photometric determination of the amount of protein.

Coomassie Brilliant Blue Assay with improved sensitivity

The invention relates to binding partners of the placental growth factor (or placenta growth factor, PIGF), especially antibodies directed against the placental growth factor, and production and use thereof.

Binding partners of the placental growth factor, especially antibodies directed against the placental growth factor, and production and use thereof

The invention relates to binding partners of the placental growth factor (or placenta growth factor, PlGF), especially antibodies directed against the placental growth factor, and production and use thereof.

A homogeneous method for determining the enzymatic activity of an analyte in a sample permits simultaneous determination of the amount of enzyme in the same reaction mixture and determination of enzyme activators or inhibitors.

Homogeneous activity test for determining enzymatic reactions

The present invention relates to a diagnostic method for identifying persons with genetically related hetero- or homozygous expression of the MR I variant of factor VII-activating protease (FSAP). The heterozygous or homozygous presence of an MR I polymorphism can be identified by a differential modulation of the FSAP activity.

Diagnostic method for identifying carriers of the Marburg I variant of factor VII-activating protease (FSAP) on the basis of differential modulation of FSAP activity

Growing community of inventors

Lahntal-Sterzhausen, Germany

Frank Vitzthum